 |
More: HIV Management 2008: The New York Course NY Course 2008: Recent Additions to ART Classes CME April 24 - 25, 2008, New York, NY Author Information and Disclosures This activity was developed in collaboration with HIV Management 2008: The New York Course.
HIV Management 2008: The New York Course is an online educational collaboration between Albert Einstein College of Medicine and Medscape
Release Date: May 30, 2008; Reviewed and Renewed: July 9, 2008; Valid for credit through May 30, 2009 | Physicians - maximum of 1.5 AMA PRA Category 1 Credit(s)™ for physicians | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Legal DisclaimerThe materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity. The materials presented here were prepared by independent authors under the editorial supervision of Medscape and were developed in collaboration with the HIV Management 2008: The New York Course. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants should be able to: - Review the recommendations for the use of current available NNRTIs and summarize recent data supporting their use
- Understand the limitations of first-generation NNRTIs and establish the need for second-generation agents
- Review the data for etravirine supporting its approval, dosing, indications, and drug interactions
- Discuss new NNRTIs currently in clinical development
- Present the structure, mechanism of action, pharmacology, efficacy, toxicity, and resistance of this new class of drugs
- Project guidelines for their incorporation into clinical management strategies
- Review the HIV-1 life cycle
with emphasis on HIV-1 integrase, integration, and the mode of action of clinically relevant inhibitors
- Discuss the antiviral activity and safety profile of raltegravir and elvitegravir, the 2 clinically relevant integrase inhibitors
- Present resistance data from pivotal clinical trials for the 2 clinically relevant integrase inhibitors
- Review known drug-drug interactions
- Summarize
recommended and anticipated use of integrase inhibitors
Authors and Disclosures Edwin DeJesus, MD, FACP
Disclosure: Edwin DeJesus, MD, FACP, has disclosed that he has received grants and/or research support from Roche and Gilead. Dr. DeJesus has also disclosed that he has served as a consultant or advisor to Bristol-Myers Squibb, Gilead,
GlaxoSmithKline, Roche, and Vertex. Roy M. Gulick, MD, MPH
Disclosure: Roy M. Gulick, MD, MPH, has disclosed that he has received research grants from Gilead, Merck, Panacos, Pfizer, Schering, and Tibotec. Dr. Gulick has also disclosed that he has served as a consultant to Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Monogram, Pfizer, Roche-Trimeris, Tibotec, and Virco, and that he
has served as a Data and Safety Monitoring Board Member for Koronis. Martin H. Markowitz, MD
Disclosure: Martin H. Markowitz, MD, has disclosed that he has received grants and/or research support from Merck, Gilead, GlaxoSmithKline, Pfizer, and Tibotec. Dr. Markowitz has also disclosed that he has served as a consultant to Merck, Gilead, GlaxoSmithKline, Pfizer, and Sequoia, and that he has served on the speaker's
bureau for Merck and Gilead. |
 |
Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. All other healthcare professionals completing continuing education credit for this activity will be issued a certificate of participation.
Albert Einstein College of Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
